Compound ID | 512
WQ-3335
Class: Fluoroquinolone
| Agent Type: | Synthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | DNA synthesis inhibitor |
| Description: | Amano H, Ohsita Y, Hayashi N, Amago T, Takenaka H, Tamura K, et al. WQ-3335, a novel fluoroquinolone with enhanced activity against QRSP. 45th-Intersci-Conf-Antimicrob-Agents-Chemother 2005;185 |
| Institute where first reported: | Wakunaga Pharmaceutical Co., Ltd., Japan |
| Year first mentioned: | 2005 |
| Development status: | Experimental |
| Reason dropped: | There has not been any report of this entering clinical trials, in 2006 it was offered up for worldwide licensing. This is likely to have been dropped through no investment |
| External links: | |
| Citation: | http://business.highbeam.com/436989/article-1G1-141202226/wq-3335-wakunaga-licensing-offer-worldwide |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.